 |
PDBsum entry 1kms
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Oxidoreductase
|
PDB id
|
|
|
|
1kms
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Atomic structures of human dihydrofolate reductase complexed with NADPH and two lipophilic antifolates at 1.09 a and 1.05 a resolution.
|
 |
|
Authors
|
 |
A.E.Klon,
A.Héroux,
L.J.Ross,
V.Pathak,
C.A.Johnson,
J.R.Piper,
D.W.Borhani.
|
 |
|
Ref.
|
 |
J Mol Biol, 2002,
320,
677-693.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
The crystal structures of two human dihydrofolate reductase (hDHFR) ternary
complexes, each with bound NADPH cofactor and a lipophilic antifolate inhibitor,
have been determined at atomic resolution. The potent inhibitors
6-([5-quinolylamino]methyl)-2,4-diamino-5-methylpyrido[2,3-d]pyrimidine
(SRI-9439) and
(Z)-6-(2-[2,5-dimethoxyphenyl]ethen-1-yl)-2,4-diamino-5-methylpyrido[2,3-d]pyrimidine
(SRI-9662) were developed at Southern Research Institute against Toxoplasma
gondii DHFR-thymidylate synthase. The 5-deazapteridine ring of each inhibitor
adopts an unusual puckered conformation that enables the formation of identical
contacts in the active site. Conversely, the quinoline and dimethoxybenzene
moieties exhibit distinct binding characteristics that account for the
differences in inhibitory activity. In both structures, a salt-bridge is formed
between Arg70 in the active site and Glu44 from a symmetry-related molecule in
the crystal lattice that mimics the binding of methotrexate to DHFR.
|
 |
 |
 |
|
 |
|
 |
Figure 3.
Figure 3. The inhibitors bind in the hDHFR active site in
an unambiguous conformation. In this stereoview, rotated vert,
similar 180° from the orientation of Figure 1, (a) SRI-9439
and (b) SRI-9662 are shown as found in the hDHFR/NADPH ternary
complexes. The 1.5 Å resolution F[O] -F[C] electron
density maps, contoured at 2.5 s, show the positive electron
density in the active site prior to the addition of either
inhibitor to the molecular models. Ligands are colored as
before; the protein C atoms are sea-green. Selected hydrogen
bonds are shown by lines (broken lines if >3.0 Å). Note
especially the hydrogen bonds between the 5-deazapteridine ring
and Glu30, and the distinct water-mediated hydrogen bonds to the
lipophilic moieties.
|
 |
Figure 5.
Figure 5. The 5-deazapteridine rings of both inhibitors
pucker dramatically upon binding to hDHFR. (a) The bound
conformations of both SRI-9439 (C, gray; N, blue) and SRI-9662
(C, steel-blue; N, cyan) exhibit a pronounced puckering in the
5-deazapteridine ring, which allows optimal interactions with
hDHFR. Despite the conformational constraint of the cis double
bond, SRI-9662 occupies a similar spatial region as SRI-9439.
(b) The 5-deazapteridine ring of SRI-9439 (and SRI-9662) is much
more puckered than the deazapteridine rings of unbound
trimetrexate (TMQ; C, gold; N, cyan) or piritrexim (PTX; C, tan;
N, cyan). (c) PTX bound to hDHFR (Leu22Phe mutant[51.]) is
canted in the active site compared to SRI-9439.
|
 |
|
 |
 |
|
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(2002,
320,
677-693)
copyright 2002.
|
 |
|
|
|
|
 |